-
1
-
-
0027412627
-
The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis
-
Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993;259:1318-20. (Pubitemid 23100269)
-
(1993)
Science
, vol.259
, Issue.5099
, pp. 1318-1320
-
-
Miyata, T.1
Takeda, J.2
Iida, Y.3
Yamada, N.4
Inoue, N.5
Takahashi, M.6
Maeda, K.7
Kitani, T.8
Kinoshita, T.9
-
2
-
-
0027310539
-
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria
-
DOI 10.1016/0092-8674(93)90250-T
-
Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-11. (Pubitemid 23159009)
-
(1993)
Cell
, vol.73
, Issue.4
, pp. 703-711
-
-
Takeda, J.1
Miyata, T.2
Kawagoe, K.3
Iida, Y.4
Endo, Y.5
Fujita, T.6
Takahashi, M.7
Kitani, T.8
Kinoshita, T.9
-
3
-
-
0028057618
-
Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria
-
DOI 10.1056/NEJM199401273300404
-
Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 1994;330:249-55. (Pubitemid 24034137)
-
(1994)
New England Journal of Medicine
, vol.330
, Issue.4
, pp. 249-255
-
-
Miyata, T.1
Yamada, N.2
Iida, Y.3
Nishimura, J.4
Takeda, J.5
Kitani, T.6
Kinoshita, T.7
-
4
-
-
28444483571
-
Diagnosis and management of paroxysmal nocturnal hemoglobinuria
-
DOI 10.1182/blood-2005-04-1717
-
Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699-709. (Pubitemid 41739003)
-
(2005)
Blood
, vol.106
, Issue.12
, pp. 3699-3709
-
-
Parker, C.1
Omine, M.2
Richards, S.3
Nishimura, J.-I.4
Bessler, M.5
Ware, R.6
Hillmen, P.7
Luzzatto, L.8
Young, N.9
Kinoshita, T.10
Rosse, W.11
Socie, G.12
-
5
-
-
69249221393
-
How I treat paroxysmal nocturnal hemoglobinuria
-
Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009;113:6522-7.
-
(2009)
Blood
, vol.113
, pp. 6522-6527
-
-
Brodsky, R.A.1
-
6
-
-
79957546158
-
Management of paroxysmal nocturnal haemoglobinuria: A personal view
-
Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol 2011;153:709-20.
-
(2011)
Br J Haematol
, vol.153
, pp. 709-720
-
-
Luzzatto, L.1
Gianfaldoni, G.2
Notaro, R.3
-
7
-
-
0028802443
-
Natural history of paroxysmal nocturnal hemoglobinuria
-
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-8.
-
(1995)
N Engl J Med
, vol.333
, pp. 1253-1258
-
-
Hillmen, P.1
Lewis, S.M.2
Bessler, M.3
Luzzatto, L.4
Dacie, J.V.5
-
8
-
-
16044365965
-
Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors
-
DOI 10.1016/S0140-6736(95)12360-1
-
Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet 1996;348:573-7. (Pubitemid 26283888)
-
(1996)
Lancet
, vol.348
, Issue.9027
, pp. 573-577
-
-
Socie, G.1
Mary, J.-Y.2
De Gramont, A.3
Rio, B.4
Leporrier, M.5
Rose, C.6
Heudier, P.7
Rochant, H.8
Cahn, J.-Y.9
Gluckman, E.10
-
9
-
-
2442532784
-
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan
-
DOI 10.1097/01.md.0000126763.68170.46
-
Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 2004;83:193-207. (Pubitemid 38649949)
-
(2004)
Medicine
, vol.83
, Issue.3
, pp. 193-207
-
-
Nishimura, J.-I.1
Kanakura, Y.2
Ware, R.E.3
Shichishima, T.4
Nakakuma, H.5
Ninomiya, H.6
Decastro, C.M.7
Hall, S.8
Kanamaru, A.9
Sullivan, K.M.10
Mizoguchi, H.11
Omine, M.12
Kinoshita, T.13
Rosse, W.F.14
-
10
-
-
35948959015
-
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
-
DOI 10.1038/nbt1344, PII NBT1344
-
Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-64. [Erratum, Nat Biotechnol 2007;25:1488.] (Pubitemid 350076509)
-
(2007)
Nature Biotechnology
, vol.25
, Issue.11
, pp. 1256-1264
-
-
Rother, R.P.1
Rollins, S.A.2
Mojcik, C.F.3
Brodsky, R.A.4
Bell, L.5
-
11
-
-
60649118722
-
Eculizumab for paroxysmal nocturnal haemoglobinuria
-
Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009;373:759-67.
-
(2009)
Lancet
, vol.373
, pp. 759-767
-
-
Parker, C.1
-
12
-
-
10744228553
-
Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria
-
DOI 10.1056/NEJMoa031688
-
Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350:552-9. (Pubitemid 38160785)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.6
, pp. 552-559
-
-
Hillmen, P.1
Hall, C.2
Marsh, J.C.W.3
Elebute, M.4
Bombara, M.P.5
Petro, B.E.6
Cullen, M.J.7
Richards, S.J.8
Rollins, S.A.9
Mojcik, C.F.10
Rother, R.P.11
-
13
-
-
27144440502
-
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
-
DOI 10.1182/blood-2005-02-0564
-
Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005;106:2559-65. (Pubitemid 41510834)
-
(2005)
Blood
, vol.106
, Issue.7
, pp. 2559-2565
-
-
Hill, A.1
Hillmen, P.2
Richards, S.J.3
Elebute, D.4
Marsh, J.C.5
Chan, J.6
Mojcik, C.F.7
Rother, R.P.8
-
14
-
-
33748904355
-
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
-
DOI 10.1056/NEJMoa061648
-
Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43. (Pubitemid 44427447)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.12
, pp. 1233-1243
-
-
Hillmen, P.1
Young, N.S.2
Schubert, J.3
Brodsky, R.A.4
Socie, G.5
Muus, P.6
Roth, A.7
Szer, J.8
Elebute, M.O.9
Nakamura, R.10
Browne, P.11
Risitano, A.M.12
Hill, A.13
Schrezenmeier, H.14
Fu, C.-L.15
Maciejewski, J.16
Rollins, S.A.17
Mojcik, C.F.18
Rother, R.P.19
Luzzatto, L.20
more..
-
15
-
-
35948962168
-
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
-
DOI 10.1182/blood-2007-06-095646
-
Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;110:4123-8. (Pubitemid 350248472)
-
(2007)
Blood
, vol.110
, Issue.12
, pp. 4123-4128
-
-
Hillmen, P.1
Muus, P.2
Duhrsen, U.3
Risitano, A.M.4
Schubert, J.5
Luzzatto, L.6
Schrezenmeier, H.7
Szer, J.8
Brodsky, R.A.9
Hill, A.10
Socie, G.11
Bessler, M.12
Rollins, S.A.13
Bell, L.14
Rother, R.P.15
Young, N.S.16
-
16
-
-
41349089713
-
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
-
DOI 10.1182/blood-2007-06-094136
-
Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;111:1840-7. (Pubitemid 351451491)
-
(2008)
Blood
, vol.111
, Issue.4
, pp. 1840-1847
-
-
Brodsky, R.A.1
Young, N.S.2
Antonioli, E.3
Risitano, A.M.4
Schrezenmeier, H.5
Schubert, J.6
Gaya, A.7
Coyle, L.8
De Castro, C.9
Fu, C.-L.10
Maciejewski, J.P.11
Bessler, M.12
Kroon, H.-A.13
Rother, R.P.14
Hillmen, P.15
-
17
-
-
78751581550
-
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: The AEGIS clinical trial
-
Kanakura Y, Ohyashiki K, Shichishima T, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol 2011;93:36-46.
-
(2011)
Int J Hematol
, vol.93
, pp. 36-46
-
-
Kanakura, Y.1
Ohyashiki, K.2
Shichishima, T.3
-
18
-
-
65449188713
-
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
-
Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009;113:4094-100.
-
(2009)
Blood
, vol.113
, pp. 4094-4100
-
-
Risitano, A.M.1
Notaro, R.2
Marando, L.3
-
19
-
-
0025936774
-
Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies
-
Würzner R, Schulze M, Happe L, et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 1991;8:328-40.
-
(1991)
Complement Inflamm
, vol.8
, pp. 328-340
-
-
Würzner, R.1
Schulze, M.2
Happe, L.3
-
20
-
-
0033661188
-
Purification of complement components, regulators, and receptors by classical methods
-
van den Berg CW. Purification of complement components, regulators, and receptors by classical methods. Methods Mol Biol 2000;150:15-52.
-
(2000)
Methods Mol Biol
, vol.150
, pp. 15-52
-
-
Van Den Berg, C.W.1
-
21
-
-
84867993256
-
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
-
Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8:643-57.
-
(2012)
Nat Rev Nephrol
, vol.8
, pp. 643-657
-
-
Zuber, J.1
Fakhouri, F.2
Roumenina, L.T.3
Loirat, C.4
Frémeaux-Bacchi, V.5
-
22
-
-
79551581253
-
Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex
-
Laursen NS, Andersen KR, Braren I, Spillner E, Sottrup-Jensen L, Andersen GR. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J 2011;30:606-16.
-
(2011)
EMBO J
, vol.30
, pp. 606-616
-
-
Laursen, N.S.1
Andersen, K.R.2
Braren, I.3
Spillner, E.4
Sottrup-Jensen, L.5
Andersen, G.R.6
-
23
-
-
0030611089
-
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease
-
Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70. (Pubitemid 27386289)
-
(1997)
Journal of Clinical Investigation
, vol.100
, Issue.5
, pp. 1059-1070
-
-
Wu, J.1
Edberg, J.C.2
Redecha, P.B.3
Bansal, V.4
Guyre, P.M.5
Coleman, K.6
Salmon, J.E.7
Kimberly, R.P.8
-
24
-
-
0036464719
-
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammarIIIa gene
-
DOI 10.1182/blood.V99.3.754
-
Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
-
(2002)
Blood
, vol.99
, Issue.3
, pp. 754-758
-
-
Cartron, G.1
Dacheux, L.2
Salles, G.3
Solal-Celigny, P.4
Bardos, P.5
Colombat, P.6
Watier, H.7
-
25
-
-
20044363597
-
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia
-
DOI 10.1200/JCO.2005.06.059
-
Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 2005;23:474-81. (Pubitemid 46224224)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.3
, pp. 474-481
-
-
Treon, S.P.1
Hansen, M.2
Branagan, A.R.3
Verselis, S.4
Emmanouilides, C.5
Kimby, E.6
Frankel, S.R.7
Touroutoglou, N.8
Turnbull, B.9
Anderson, K.C.10
Maloney, D.G.11
Fox, E.A.12
|